Novel combi-molecules having egfr and dna targeting properties

Details Novel combi-molecules having egfr and dna targeting properties Novel combi-molecules having egfr and dna targeting properties

C - Chemistry, Metallurgy

07

D

C07D 239/84 (2006.01) C07D 413/12 (2006.01)

Patent

CA 2471177

A process for the synthesis of high affinity irreversible inhibitors of epidermal growth factor receptor (EGFR) having fluorescent properties and significant anti- proliferative activity is described. More specifically, the mechanism of action of ZR2002, a chimeric aminoquinazoline designed to possess mixed EGFR tyrosine kinase (TK) inhibitory and DNA targeting properties, was compared with those of ZR01, a reversible inhibitor of the same class and PD168393, a known irreversible inhibitor of EGFR. ZR2002 was shown to exhibit 4-fold stronger EGFR TK inhibitory activity than its structural homologue ZR01 but was approximately 3-fold less active than the 6-acrylamidoquinazoline PD168393. It preferentially blocked EGF and TGF.alpha.-induced cell growth over PDGF and serum. It also inhibited signal transduction in heregulin-stimulated breast tumour cells, indicating that it does not only block EGFR but also its closely related erbB2 gene product. In contrast to its structural homologues, ,ZR2002 was capable of inducing significant levels of DNA strand breaks in MDA-MB-468 cells after a short 2 h drug exposure and at a concentration as low as 10 mM.

Affiliated with

Also associated with

Rating

Novel combi-molecules having egfr and dna targeting properties does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel combi-molecules having egfr and dna targeting properties, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel combi-molecules having egfr and dna targeting properties will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1991374